Lung Cancer News and Research

Latest Lung Cancer News and Research

UNC researchers study why surgery happens less often in blacks with lung cancer

A new study led by UNC researchers that looks at newly diagnosed lung cancer patients and follows them from diagnosis forward is one of the first to give reasons why patients don't go to lung surgery and why surgery happens less often in blacks.

16 Jun 2010

Research investigates surgical outcomes of patients with NSCLC

Research published in the June edition of the Journal of Thoracic Oncology sought to investigate the time trends of surgical outcomes of patients with non-small cell lung cancer between 1979 and 2008. The incidence of lung cancer continues to rise; therefore, countermeasures to decrease death rates have become an important public health issue.

16 Jun 2010

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer. Results will provide researchers with a data needed to guide a phase 3 trial.

16 Jun 2010

ARBs may be linked with increased risk of developing cancer: US scientists

A common class of blood pressure drugs called angiotensin-receptor blockers may be linked with a slightly increased risk of developing cancer, US scientists have found.

16 Jun 2010

High vitamin B levels in blood reduce lung cancer risk: Study

Regular intake of Vitamin B complex can reduce the risk of getting lung cancer, researchers have found. The research paper in the Journal of the American Medical Association however emphasized that quitting smoking was the best method to reduce the risk of lung cancer. It is too early to say that vitamin supplements can actually prevent lung cancer say researchers. Lung cancer kills nearly 1.3 million people globally each year according to the World Health Organization and 10 to 15 percent of smokers develop lung cancer.

15 Jun 2010

Women who drink boiled coffee at lower risk of breast cancer

Women who drink Scandinavian boiled coffee, which chemically resembles of French press and Turkish/Greek coffee, more than four times a day run a lower risk of developing breast cancer than women who drink coffee less than once a day. This is shown by Lena Nilsson and her associates at Umeå University in an article in the journal Cancer Causes & Control.

15 Jun 2010

Researchers discover microRNA biomarkers to treat patients with SCLC

Researchers at the Translational Genomics Research Institute, the Van Andel Research Institute and the Virginia G. Piper Cancer Center at Scottsdale Healthcare have discovered a biomarker that could help in the treatment of patients with an aggressive type of lung cancer.

15 Jun 2010

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer. TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.

14 Jun 2010

ARBs increase risk of cancer: Study

University Hospitals Case Medical Center cardiologists have uncovered new research showing an increased risk of cancer with a group of blood pressure medications known as angiotensin-receptor blockers (ARBs).

14 Jun 2010

Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the final analysis of the Phase 3 NExUS (NSCLC research Experience Utilizing Sorafenib) trial evaluating Nexavar® (sorafenib) tablets in patients with advanced non-squamous non-small cell lung cancer (NSCLC) showed that the study did not meet its primary endpoint of improving overall survival in the first-line setting.

14 Jun 2010

Report highlights deprivation gap caused by late diagnosis of cancer, differences in treatment choices

There could be as many as 14,000 fewer cases of cancer each year in England if everyone was as healthy as the richest 20 per cent in the country. And the difference between the classes is more marked among men than women. Among men there were 21 per cent more cases of cancer in the most deprived areas compared to the least deprived, whereas the gap among women was 11 per cent.

14 Jun 2010

Baron & Budd, P.C. attorney supports Give a Scan Program for lung cancer research

Baron & Budd, P.C. attorney John Langdoc expressed his support and enthusiasm for a new and innovative initiative by the Washington, D.C.-based Lung Cancer Alliance —called Give a Scan—to make CT Scans and clinical data donated by cancer patients easily accessible to lung cancer researchers. LCA would "de-identify" the scans and data before making the information available to researchers.

11 Jun 2010

FDA grants orphan drug designation for ICT-107

ImmunoCellular Therapeutics announced today that the U.S. Food and Drug Administration has granted orphan drug designation for ICT-107, the company's dendritic cell-based cancer vaccine candidate which targets glioblastoma multiforme. As a result of the orphan drug status, ImmunoCellular will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of up to seven years.

11 Jun 2010

Family caregivers experience typical patterns of wellbeing and distress their relatives going through

Family carers need to be supported throughout the whole illness of their loved ones as they witness and share much of the experience of the dying person, according to research published on bmj.com today.

11 Jun 2010

iCAD to supply CAD technology for mammography to VA, Department of Defense Hospitals

iCAD, Inc., an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announced it has signed an agreement with the Defense Supply Center to provide federal healthcare facilities including Veteran's Administration (VA) and Department of Defense Hospitals with its Computer-Aided Detection (CAD) technology for mammography.

11 Jun 2010

Study suggests potential of ARC man-made compound in combination with Abbott's ABT-737 for cancer

Adding a second agent may make a new, experimental anti-cancer drug effective against a wide range of cancers, researchers at the University of Illinois at Chicago College of Medicine have found.

10 Jun 2010

People who smoke immediately after waking may be at risk for lung cancer: Study

People who smoke their first cigarette within minutes after waking up have much higher levels of cotinine, a by-product of nicotine when processed by the body, than those who wait to smoke, regardless of the number of cigarettes smoked.

10 Jun 2010

Veracyte announces completion of Series B round

Veracyte, Inc. announced today the successful completion of its Series B round, a key milestone toward the company's first product launch later this year. The South San Francisco biotechnology company is committed to pioneering molecular cytology diagnostics to improve patient care and lower health care costs. This round was led by Domain Associates with significant participation from Veracyte's founding investors including Kleiner Perkins Caufield & Byers (KPCB), TPG Biotech (TPG), and Versant Ventures.

10 Jun 2010

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

GE Healthcare, a unit of the General Electric Company, today will present results of a phase 1 study of anti-[18F]FACBC at the 57th annual meeting of the Society of Nuclear Medicine in Salt Lake City, Utah. The presentation closely follows the launch of the phase 2 clinical development program for anti-[18F]FACBC, which was initially discovered and developed by Emory University, Atlanta, Georgia, and was licensed to Nihon Medi-Physics Co., Ltd. (NMP) of Japan.

9 Jun 2010

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced approval by the Norwegian Medicines Agency ('Statens Legemiddelverk') to test a combination of LTX-315 and GV1001 as vaccine therapy in patients with resected tumours. Lytix Biopharma CEO Gunnar Salid states, "We are delighted to announce the approval of our joint study to test a combination of two very interesting experimental drugs.

9 Jun 2010

Lung Cancer News and Research

Latest Lung Cancer News and Research

UNC researchers study why surgery happens less often in blacks with lung cancer

Research investigates surgical outcomes of patients with NSCLC

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

ARBs may be linked with increased risk of developing cancer: US scientists

High vitamin B levels in blood reduce lung cancer risk: Study

Women who drink boiled coffee at lower risk of breast cancer

Researchers discover microRNA biomarkers to treat patients with SCLC

Telormedix initiates Phase I/II clinical study of TMX-101 for treating NMIBC

ARBs increase risk of cancer: Study

Nexavar does not meet primary endpoint in Phase 3 NExUS trial for advanced NSCLC

Report highlights deprivation gap caused by late diagnosis of cancer, differences in treatment choices

Baron & Budd, P.C. attorney supports Give a Scan Program for lung cancer research

FDA grants orphan drug designation for ICT-107

Family caregivers experience typical patterns of wellbeing and distress their relatives going through

iCAD to supply CAD technology for mammography to VA, Department of Defense Hospitals

Study suggests potential of ARC man-made compound in combination with Abbott's ABT-737 for cancer

People who smoke immediately after waking may be at risk for lung cancer: Study

Veracyte announces completion of Series B round

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in